SCHEMBL3707943

SCHEMBL3707943

Cc1ccc(-c2c(NC(=O)Cc3ccc(Cl)cc3)nn3c(C)ccnc23)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 5/20 0.43
KCNQ2 O43526 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 2/20 0.41
KMT2A Q03164 1/20 0.39
MAPK14 Q16539 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
WNT3A P56704 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
NPBWR1 P48145 1/20 0.39
MCHR1 Q99705 1/20 0.39
FFAR2 O15552 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3701916 0.82 MAPK14 (0.52) KCNQ3KCNQ2SMN1; SMN2KMT2AMAPK14
SCHEMBL3695805 0.81 ALDH1A1 (0.46) KCNQ3KCNQ2SMN1; SMN2MAPTKMT2A
SCHEMBL3707687 0.81 ROCK1 (0.49) KCNQ2KMT2ARAB9AALDH1A1GAA
SCHEMBL3707258 0.79 MAPK14 (0.48) KCNQ3KCNQ2HPGDMAPTKMT2A
SCHEMBL3714832 0.79 KCNQ3 (0.61) KCNQ3KCNQ2SMN1; SMN2KMT2ANPC1
SCHEMBL3701012 0.79 KCNQ3 (0.56) KCNQ3KCNQ2HPGDMAPTNPC1
SCHEMBL3706811 0.75 MAPT (0.43) KCNQ3KCNQ2HPGDMAPTMAPK14
SCHEMBL3696615 0.75 ALDH1A1 (0.46) SMN1; SMN2WNT3AKDM4EALDH1A1GAA
SCHEMBL3703621 0.75 KCNQ3 (0.58) KCNQ3KCNQ2SMN1; SMN2HPGDMAPK14
SCHEMBL3709636 0.74 KCNQ3 (0.53) KCNQ3KCNQ2SMN1; SMN2KMT2AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 KCNQ3 4/4885KCNQ2 2/4885SMN1; SMN2 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.